Table 3.
Treatment profiles of anti‐PD‐1 antibody retreatment
| Anti‐PD‐1 antibody retreatment | Nivolumab | Pembrolizumab |
|---|---|---|
| n = 7 | n = 8 | |
| Median cycle length, months (range) | 4 (1–7) | 4 (1–14) |
| PD‐L1 expression | ||
| TPS ≤50%, n (%) | 0 (0.0) | 0 (0.0) |
| 1% ≤ TPS < 50%, n (%) | 1 (14.3) | 4 (50.0) |
| TPS <1%, n (%) | 4 (57.1) | 1 (12.5) |
| NE, n (%) | 2 (28.6) | 3 (37.5) |
| PFS, months (range) | 1.9 (0.43–3.0) | 2.8 (0.47–13.4) |
| Best response during anti‐PD‐1 antibody treatment | ||
| PD, n (%) | 5 (71.4) | 4 (50.0) |
| SD, n (%) | 1 (14.3) | 3 (37.5) |
| NE, n (%) | 1 (14.3) | 1 (12.5) |
| Treatment between anti‐PD‐L1 antibody and anti‐PD‐1 antibody | ||
| Cytotoxic chemotherapy | ||
| CBDCA+nabPTX/PTX ± BV, n (%) | 1 (14.3) | 0 (0.0) |
| CBDCA+PEM ± BV, n (%) | 0 (0.0) | 0 (0.0) |
| DTX + RAM, n (%) | 3 (42.9) | 1 (12.5) |
| Others, n (%) | 0 (0.0) | 2 (25.0) |
anti‐PD‐1, anti‐programmed death 1; BV, bevacizumab; CBDCA, carboplatin; DTX, docetaxel; nabPTX, nanoparticle albumin‐bound paclitaxel; NE, not evaluated; PD, progressive disease; PD‐L1, programmed death‐ligand 1; PEM, pemetrexed; PFS, progression‐free survival; RAM, ramucirumab; SD, stable disease; TPS, tumor proportion score.